Shots:
- Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences to support development of sac-TMT, currently in 15 global P-III trials across multiple cancers, including breast, endometrial, and lung
- As per the deal, Blackstone will provide Merck $700M to help fund sac-TMT development through 2026. In return, Blackstone is eligible for low-to-mid single-digit royalties if sac-TMT wins US approval for first-line triple-negative breast cancer based on the TroFuse-011 trial
- Sac-TMT continues under Merck’s exclusive collaboration with Kelun-Biotech. Merck retains full control over development, manufacturing, and commercialization, while Blackstone receives no rights to the drug
Ref: Merck | Image: Merck & Blackstone Life Sciences | Press Release
Related News:- Boehringer Ingelheim and CDR-Life Expand their Partnership with a Global Licensing Deal for CDR111
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
